LexDanaLexDanabeta
Inventor

David Juergen Wustrow

Inventor
Ann Arbor, MI, US

Overview

65→
Patents
1991–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 65 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
C07DHeterocyclic compounds28%
A61KPreparations for medical, dental or toiletry purposes18%
C07CAcyclic or carbocyclic compounds13%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium4%
Y02ATechnologies for adaptation to climate change3%
C07BGeneral methods of organic chemistry2%
A01NPreservation of bodies of humans or animals or plants or parts thereof1%
C07KPeptides1%
PatentTitleYear
11,084,829Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof202111,046,699Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses202110,940,117Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof202110,722,514Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof202010,716,760Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof202010,683,280Chemokine receptor modulators and uses thereof202010,604,526Chemokine receptor modulators and uses thereof202010,246,462Chemokine receptor modulators and uses thereof201910,179,787Chemokine receptor modulators and uses thereof201910,174,005Fused pyrimidines as inhibitors of p97 complex201910,010,554Fused pyrimidines as inhibitors of P97 complex20189,868,722'Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex'20189,844,554Prodrugs of metopimazine20179,828,363Fused pyrimidines as inhibitors of P97 complex20179,597,292'Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof'20179,475,824'Fused pyrimidines as inhibitors of p97 complex'20169,133,204'5-membered heterocyclic amides and related compounds'20159,062,026'Fused pyrimidines and substituted quinazolines as inhibitors of p97'20158,952,006'Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use'20158,431,593'Heteroaryl amide derivatives'20138,377,956'Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence'20138,344,028'Gamma-amino-butyric acid derivatives as GABAB receptor ligands'20137,517,909'Amino acids with affinity for the α2δ-protein'20097,491,835'Prodrugs of amino acids with affinity for the α2δ-protein'20097,432,299'Method of treatment for sexual dysfunction'20087,381,747'Alpha 2 delta ligands for post-traumatic stress disorder'20087,250,433'Tetrazole and oxadiazolone substituted β-amino acid derivatives'20077,189,747'Method of treating noninflammatory cartilage damage'20077,164,034'Alpha2delta ligands for fibromyalgia and other disorders'20077,138,542'Method of treating tinnitus'20067,122,678'Cyclic amino acids and derivatives thereof useful as pharmaceutical agents'20067,064,147'Amino acids with affinity for the α-2-delta-protein'20067,030,267'Cycloproply β-amino acid derivatives'20067,026,505'Method of treating tinnitus'20066,921,835'Cyclic amino acids and derivatives thereof useful as pharmaceutical agents'20056,809,119'Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases'20046,642,398'Mono-and disubstituted 3-propyl gamma-aminobutyric acids'20036,635,673'Cyclic amino acids and derivatives thereof useful as pharmaceutical agents'20036,632,831'Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases'20036,627,771'Gamma amino butyric and acid analogs'20036,620,829'Method of treating noninflammatory cartilage damage'20036,545,022'4(3)substituted-4(3)-aminomethyl-(thio)pyran or piperidine derivatives (gabapentin analogues), their preparation and their use in the treatment of neurological disorders'20036,521,650'Amines as pharmaceutical agents'20036,518,289'1-substituted-1-aminomethyl-cycloalkane derivatives (gabapentin analogues), their preparation and their use in the treatment of neurological disorders'20036,436,974'Amino heterocycles useful as pharmaceutical agents'20026,245,801'Branched alkyl pyrrolidine-3-carboxylic acids'20016,177,422'Benzoxazinone dopamine D4 receptor antagonists'20016,153,650'Substituted gamma aminobutyric acids as pharmaceutical agents'20006,087,364'Dopamine D4 receptor antagonists'20005,977,110'Substituted cyclohexylamines as central nervous systems agents'19995,945,421'Dopamine D4 receptor antagonists'19995,922,719'Coumarin dopamine D4 receptor antagonists'19995,710,277'Process for R (+) 1,2,3,6-tetrahydro-4-phenyl-1-›(3-phenyl-3-cyclohexen-1-yl)methyl!pyridi ne, a central nervous system agent'19985,532,226'Trifluoromethybenzylphosphonates useful in treating osteoporosis'19965,430,047'Neurotensin antagonists'19955,409,931'1,3-substituted cycloalkenes and cycloalkanes as central nervous system agents'19955,407,916'Neurotensin mimetics as central nervous system agents'19955,314,896'1,3-substituted cycloalkenes and cycloalkanes as central nervous system agents'19945,300,687'Trifluoromethylbenzylphosphonates useful in treating osteoporosis'19945,206,233'Substituted thiazepines as central nervous system agents'19935,187,280'Substituted tetrahydropyridines and their use as central nervous system agents'19935,118,691'Substituted tetrahydropyridines as central nervous system agents'19925,089,497'Substituted piperazines as central nervous system agents'19925,075,440'Novel pyrido[2,3-f](1,4)thiazepines and pyrido[3,2-b](1,5)benzothiazepines'19915,045,550'Substituted tetrahydropyridines as central nervous system agents'1991

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1991–2008Patents assigned to WARNER LAMBERT CO (31)· patent assignee history
1991–2009Based in Ann Arbor, MI, US· patent location history
2003–2009Patents assigned to PFIZER (9)· patent assignee history
2013–2020Patents assigned to XENOPORT INC (5)· patent assignee history
2013Based in Saratoga, CA, US· patent location history
2015–2019Patents assigned to CLEAVE BIOSCIENCES INC (6)· patent assignee history
2015–2021Based in Los Gatos, CA, US· patent location history
2020–2021Patents assigned to RAPT THERAPEUTICS INC (5)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
WARNER LAMBERT CO311991–2008
PFIZER92003–2009
CLEAVE BIOSCIENCES INC62015–2019
RAPT THERAPEUTICS INC52020–2021
XENOPORT INC52013–2020
Locations
LocationPatentsSpan
Ann Arbor, MI, US431991–2009
Los Gatos, California, US192015–2021
Saratoga, California, US32013